Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1993-04-30
1995-01-31
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
514554, 514912, A61K 31195, A61K 31205
Patent
active
053859391
ABSTRACT:
A composition for the inhibition of the abnormal postnatal axial growth of the eye of a maturing animal which comprises a pharmaceutically effective amount of a gamma aminobutyric acid antagonist relatively selective for GABA.sub.B receptors in the cells of the eye, said antagonist present in a carrier or diluent suitable for ocular administration. A suitable antagonist is 2-OH saclofen.
REFERENCES:
patent: 4865599 (1989-09-01), Chiou
patent: 5055302 (1991-10-01), Laties et al.
patent: 5122522 (1992-06-01), Laties et al.
Mosinger et al., "GABA-like Immunoreactivity in the Vertebrate Retina: A Species Comparison", Exp. Eye Res. 42: 631-644 (1986).
Fiszer De Plazas et al., "Light and Dark Adaptation Influences GABA Receptor Sites in the Chick Retina", Neurochemical Research, 11: 973-981 (1986).
Ikeda, et al., "Actions of baclofen and phaclofen upon ON- and OFF-ganglion cells in the cat retina," European J. of Pharm. 190: 1 (1990).
Laties Alan M.
Stone Richard A.
Fay Zohreh
The Trustees of the University of Pennsylvania
LandOfFree
GABA-ergic modulation of eye growth does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with GABA-ergic modulation of eye growth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and GABA-ergic modulation of eye growth will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1102574